SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2013
(Exact Name of Registrant as Specified in Its Charter)
Registrant’s telephone number, including area code (866) 644-7811
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 7.01. Regulation FD Disclosure.
On February 6, 2013, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), issued a press release announcing that it will present preclinical data on its long-acting clotting Factor VIIa (Factor VIIa-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (the “EAHAD Congress”), which is being held in Warsaw, Poland. The Company will present its data from 5:00-8:00 p.m. local time. A copy of the press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.
At the EAHAD Congress, the Company will additionally present a poster presentation, a copy which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.
ITEM 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.